<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hillemanns, Peter</style></author><author><style face="normal" font="default" size="100%">Klaus Friese</style></author><author><style face="normal" font="default" size="100%">Christian Dannecker</style></author><author><style face="normal" font="default" size="100%">Stefanie Klug</style></author><author><style face="normal" font="default" size="100%">Ulrike Seifert</style></author><author><style face="normal" font="default" size="100%">Thomas Iftner</style></author><author><style face="normal" font="default" size="100%">Juliane Hädicke</style></author><author><style face="normal" font="default" size="100%">Thomas Löning</style></author><author><style face="normal" font="default" size="100%">Lars Horn</style></author><author><style face="normal" font="default" size="100%">Dietmar Schmidt</style></author><author><style face="normal" font="default" size="100%">Hans Ikenberg</style></author><author><style face="normal" font="default" size="100%">Manfred Steiner</style></author><author><style face="normal" font="default" size="100%">Ulrich Freitag</style></author><author><style face="normal" font="default" size="100%">Uwe Siebert</style></author><author><style face="normal" font="default" size="100%">Gaby Sroczynski</style></author><author><style face="normal" font="default" size="100%">Willi Sauerbrei</style></author><author><style face="normal" font="default" size="100%">Matthias W Beckmann</style></author><author><style face="normal" font="default" size="100%">Marion Gebhardt</style></author><author><style face="normal" font="default" size="100%">Michael Friedrich</style></author><author><style face="normal" font="default" size="100%">Karsten Münstedt</style></author><author><style face="normal" font="default" size="100%">Schneider, Achim</style></author><author><style face="normal" font="default" size="100%">Kaufmann, Andreas</style></author><author><style face="normal" font="default" size="100%">K Ulrich Petry</style></author><author><style face="normal" font="default" size="100%">Axel P A Schäfer</style></author><author><style face="normal" font="default" size="100%">Pawlita, Michael</style></author><author><style face="normal" font="default" size="100%">Joachim Weis</style></author><author><style face="normal" font="default" size="100%">Anja Mehnert</style></author><author><style face="normal" font="default" size="100%">Mathias Fehr</style></author><author><style face="normal" font="default" size="100%">Christoph Grimm</style></author><author><style face="normal" font="default" size="100%">Olaf Reich</style></author><author><style face="normal" font="default" size="100%">M. Arbyn</style></author><author><style face="normal" font="default" size="100%">Jos Kleijnen</style></author><author><style face="normal" font="default" size="100%">Simone Wesselmann</style></author><author><style face="normal" font="default" size="100%">Monika Nothacker</style></author><author><style face="normal" font="default" size="100%">Markus Follmann</style></author><author><style face="normal" font="default" size="100%">Thomas Langer</style></author><author><style face="normal" font="default" size="100%">Matthias Jentschke</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Prevention of Cervical Cancer: Guideline of the DGGG and the DKG (S3 Level, AWMF Register Number 015/027OL, December 2017) - Part 1 with Introduction, Screening and the Pathology of Cervical Dysplasia.</style></title><secondary-title><style face="normal" font="default" size="100%">Geburtshilfe Frauenheilkd</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">cervical cancer</style></keyword><keyword><style  face="normal" font="default" size="100%">cervical intraepithelial neoplasia (CIN)</style></keyword><keyword><style  face="normal" font="default" size="100%">cervical precancerous condition</style></keyword><keyword><style  face="normal" font="default" size="100%">HPV</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2019 Feb</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">79</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;&lt;strong&gt;AIMS&lt;/strong&gt;&lt;br&gt;
Annual opportunistic screening for cervical carcinoma has been carried out in Germany since 1971. The creation of this S3 guideline meets an important need, outlined in the National Cancer Plan, with regard to screening for cervical cancer, as the guideline aims to provide important information and support for planned organized screening for cervical cancer in Germany.&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;METHODS&lt;/strong&gt;&lt;br&gt;
With the financial support of German Cancer Aid, 21 professional societies developed evidence-based statements and recommendations (classified using the GRADE system) for the screening, management and treatment of precancerous conditions of the cervix. Two independent scientific institutes compiled systematic reviews for this guideline.&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;RECOMMENDATIONS&lt;/strong&gt;&lt;br&gt;
The first part of this short summary presents the pathological basis and considers various questions related to screening for cervical cancer. As also reported in earlier reviews, the meta-analysis by Kleijnen Systematic Reviews showed that HPV-based screening offers better protection against invasive cervical cancer compared to cytology-based screening. The authors of this guideline therefore recommend - in accordance with the guideline of the Joint National Committee of Germany (Gemeinsamer Bundesauschuss, G-BA) - that women aged 35 and above should be examined at regular intervals (at least every 3 years) and undergo HPV-based screening. Co-testing can also be carried out. Women between the ages of 20 and 35 should have cytological screening every 2 years.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">2</style></issue></record></records></xml>